drugset / Trial / NCT06004752
Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly
NaSingle-groupOpen-labelTreatment
Summary
For elderly patients who cannot tolerate anti-thymocyte globulin (ATG) treatment, the addition of avatrombopag (AVA), which has a slight adverse reaction, can theoretically improve the hematological response rate in elderly patients with non-severe aplastic anemia (NSAA) without significantly increasing adverse reactions. Based on this, this study treated NSAA patients older than 60 with AVA combined with CsA to evaluate the hematological response rate and safety of AVA in the elderly who could not tolerate ATG therapy.
Timeline
- Start
- 2023-08-17
- Primary completion
- 2024-08
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 40 mg | Oral |
| Subject | Avatrombopag | Small molecule | 60 mg | Oral |
| Subject | Cyclosporine | Peptide | 3 mg/kg | Oral |
| Subject | Cyclosporine | Peptide | 5 mg/kg | Oral |